PolyPid Ltd. (PYPD)
PolyPid Ltd.
18 Hasivim Street
Petah Tikva 4959376
Israel
972 7 4719 5700
https://www.polypid.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 59
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Dikla Czaczkes Akselbrad | CEO & Director | 347.88k | N/D | 1973 |
| Mr. Jonny Missulawin | Chief Financial Officer | 186.96k | N/D | 1987 |
| Ms. Dalit Hazan | Executive Vice President of R&D and Clinical & Regulatory Affairs | 272.38k | N/D | 1971 |
| Mr. Ori Warshavsky | Chief Operating Officer - US | 340.89k | N/D | 1978 |
| Ms. Maria Rubin | Vice President of Operations | N/D | N/D | N/D |
| Mr. Tal Vilnai | General Counsel & Corporate Secretary | N/D | N/D | N/D |
| Ms. Rivi Lev-ari | Vice President of Human Resource | N/D | N/D | N/D |
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer | N/D | N/D | N/D |
Descripción
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Gestión corporativa
La calificación ISS Governance QuickScore de PolyPid Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
